The current challenges of multi-drug resistance development in human pathogenic microorganisms are engaging researchers in exploring the field of nanotechnology-derived approaches and products as new tools of key developments for manufacturing effective antimicrobials. But, the real contributions are still uncertain. Although there are several budding leads of nanotechnology and the growing trends in publications and patents, therapeutic microbiological applications have not yet made it to the market. Numerous reasons could explain the scarcity of commercial applications. These include high initial production investments, new nanotechnology regulation in the developed and developing countries, and public perception. The rapid progress of nanotechnology in other key areas may over time be transferred to therapeutic microbiological applications as well, and accelerate their development.
展开▼
